Referral Patterns and Adjuvant Chemotherapy Use in Patients With Stage II Colon Cancer

被引:17
作者
Kirkpatrick, Haskell M. [1 ,2 ]
Aitelli, Cristi L. [1 ,2 ]
Qin, Huanying [3 ]
Becerra, Carlos [1 ,2 ]
Lichliter, Warren E. [4 ]
McCollum, A. David [1 ,2 ]
机构
[1] Baylor Univ, Texas Oncol PA, Baylor Sammons Canc Ctr, Med Ctr, Dallas, TX 75246 USA
[2] Baylor Univ, Med Ctr, Dept Oncol, Dallas, TX USA
[3] Ctr Hlth Care Res, Dallas, TX USA
[4] Baylor Univ, Med Ctr, Dept Colorectal Surg, Dallas, TX USA
关键词
Bowel obstruction; Comorbidity; Patient selection; T stage; AMERICAN JOINT COMMITTEE; MEDICAL ONCOLOGISTS; POOLED ANALYSIS; FLUOROURACIL; LEUCOVORIN; THERAPY; OXALIPLATIN; LEVAMISOLE; SURVIVAL; EFFICACY;
D O I
10.3816/CCC.2010.n.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Little is known about the actual rate of use of adjuvant chemotherapy in stage II colon cancer and about referral patterns that give patients access to this treatment. Patients and Methods: We searched the tumor registry at Baylor University Medical Center at Dallas to identify patients with stage II colon cancer who underwent resection between 1995 and 2003. The rates of referral to medical oncology and adjuvant chemotherapy use were calculated and potential predictive variables were analyzed using univariate and multivariate techniques. Results: We identified 287 patients with stage II colon cancer. A total of 160 patients (56%) were referred to a medical oncologist. Eighty patients (28%) received adjuvant chemotherapy. Age < 50 years, private insurance status, lower comorbidity score, higher T stage, and poor tumor differentiation were significant predictors of adjuvant chemotherapy use (P <= .05). Conclusion: Variability and controversy exist over the use of adjuvant chemotherapy in patients with stage II colon cancer. Our study suggests many patients are not referred to a medical oncologist and may not be fully informed of all treatment options. Referral patterns become more important as a better understanding of recurrence risk is achieved and patient selection for adjuvant chemotherapy is optimized.
引用
收藏
页码:150 / 156
页数:7
相关论文
共 25 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]   Stage II colon cancer prognosis prediction by tumor gene expression profiling [J].
Barrier, Alain ;
Boelle, Pierre-Yves ;
Roser, Francois ;
Gregg, Jennifer ;
Tse, Chantal ;
Brault, Didier ;
Lacaine, Francois ;
Houry, Sidney ;
Huguier, Michel ;
Franc, Brigitte ;
Flahault, Antoine ;
Lemoine, Antoinette ;
Dudoit, Sandrine .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4685-4691
[3]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]  
Compton C, 2000, CANCER-AM CANCER SOC, V88, P1739, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO
[6]  
2-T
[7]   Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis [J].
Des Guetz, Gaetan ;
Schischmanoff, Olivier ;
Nicolas, Patrick ;
Perret, Gerard-Yves ;
Morere, Jean-Francois ;
Uzzan, Bernard .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) :1890-1896
[8]   Impact of referral patterns on the use of chemotherapy for lung cancer [J].
Earle, CC ;
Neumann, PJ ;
Gelber, RD ;
Weinstein, MC ;
Weeks, JC .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1786-1792
[9]   Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer [J].
Erlichman, C ;
O'Connell, M ;
Kahn, M ;
Marsoni, S ;
Torri, V ;
Tardio, B ;
Zaniboni, A ;
Pancera, G ;
Martignoni, G ;
Labianca, R ;
Barni, A ;
Seitz, JF ;
Milan, C ;
Bedenne, L ;
Giovannini, M ;
Letreut, YP ;
Skillings, J ;
Shepard, L ;
Zee, B ;
Petrioli, R ;
Francini, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1356-1363
[10]   Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group [J].
Figueredo, A ;
Charette, ML ;
Maroun, J ;
Brouwers, MC ;
Zuraw, L .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3395-3407